Matteo D.
- Country
- Italy
- Department
- SC Onclogia Medica
Research Overview
- Safety, Pharmacokinetics, and Efficacy of BAY 2416964 (AhR Inhibitor) and Pembrolizumab in Adults with Advanced Solid Tumors
- Phase 2 Open‑Label Study of BMS‑986504 Monotherapy and Combination Therapy in Advanced/Metastatic Solid Tumors with Homozygous MTAP Deletion
- A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
Data & Insights
Has run more than one trial at 53 of 141 partner sites.
Specializations
Thoracic and Upper Aerodigestive Oncology
Matteo Duca is involved in clinical research on non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, and esophageal cancer, with interest in advanced, recurrent, and biomarker-defined disease.
- Advanced lung cancer
- Head and neck squamous cell carcinoma
- Esophageal carcinoma
- Molecularly selected thoracic malignancies
His trial portfolio also includes targeted therapy and immunotherapy approaches for lung and upper gastrointestinal cancers.
Breast, Gynecologic, and Genitourinary Cancers
His oncology activity extends to breast cancer, ovarian cancer, endometrial cancer, cervical cancer, urothelial carcinoma, and renal cell carcinoma, including locally advanced and metastatic settings.
- Triple-negative breast cancer
- Ovarian cancer
- Endometrial cancer
- Urothelial carcinoma
Research interests include HER2-directed therapy, PARP inhibition, and immune checkpoint blockade across solid tumors.
Gastrointestinal and Hepatobiliary Malignancies
He is engaged in studies of colorectal cancer, gastric cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, and hepatocellular carcinoma, with attention to refractory and molecularly defined disease.
- Colorectal cancer
- Gastric and gastroesophageal junction adenocarcinoma
- Pancreatic cancer
- Hepatocellular carcinoma
These trials reflect a therapeutic focus on precision oncology and combined modality treatment in gastrointestinal cancers.
Hematologic Malignancies and Cellular Therapy
His research landscape includes lymphoma, multiple myeloma, and leukemia, together with studies in patients previously exposed to CAR T-cell therapy or other advanced hematologic treatments.
- Diffuse large B-cell lymphoma
- Classical Hodgkin lymphoma
- Multiple myeloma
- Peripheral T-cell lymphoma
His therapeutic interest also covers bispecific antibodies, immune-based regimens, and post-cellular therapy strategies.
Neurology, Neuroimmunology, and Pediatric Disorders
Matteo Duca also participates in clinical trials in myasthenia gravis, multiple sclerosis, epilepsy, migraine, and selected neurodegenerative diseases, alongside pediatric neurologic conditions.
- Generalized myasthenia gravis
- Multiple sclerosis
- Focal epilepsy
- Migraine
His portfolio further includes pediatric neuro-oncology and rare disorders such as spinal muscular atrophy and Huntington’s disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.